<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825290</url>
  </required_header>
  <id_info>
    <org_study_id>2537-15-SMC</org_study_id>
    <nct_id>NCT02825290</nct_id>
  </id_info>
  <brief_title>Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study</brief_title>
  <official_title>Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the outcomes of frozen-thawed embryo transfer (FET) success rate with
      modified luteal support - addition of a single injection of HCG and GnRH-agonist, on day of
      ET and 4 days later, respectively vs. traditional luteal support with vaginal progesterone
      only in ovulating women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background With the recent trend toward single embryo transfer (ET) adopted in an attempt to
      reduce the risk of multiple pregnancy, the remaining extra embryos are cryopreserved,
      providing further possibilities for conception after the initial fresh transfer. Moreover,
      several studies that compared fresh and frozen-thawed embryo transfer (FET) cycles in normal
      responders have demonstrated a significantly higher clinical pregnancy rate per transfer in
      the FET versus the fresh cycles.

      There are several currently employed replacement protocols for FET. The choice of protocol
      depends on the individual woman's ovarian function and convenience of the method, as well as
      on the experience gained with the method by the physicians. Whatever protocol is used, the
      success requires optimal synchronization between the embryonic stage at thawing and date of
      the endometrium within the endometrial preparation cycle. While there is a consensus
      regarding the duration, route of delivery and dosage of estrogen supplementation, and the
      optimal ultrasonographic endometrial appearance and thickness, the effect of the different
      modes of luteal support remains unclear.

      Prompted by the study demonstrating higher ongoing pregnancy rate following the transfer of
      frozen-thawed embryos in natural cycles with spontaneous LH rise compared with natural cycles
      controlled by hCG for final oocyte maturation and the reports showing improved pregnancy rate
      in patients who received a mid-luteal injection of a GnRH-agonist (0.1 mg triptorelin), the
      investigators started beginning at June 2014 to offer ovulatory patients with regular
      menstrual cycles a natural FET with modified luteal support. Starting on the day of
      spontaneous ovulation, patients received daily vaginal progesterone, supplemented by a single
      injection of HCG and GnRH-agonist, on day of ET and 4 days later, respectively.

      The results for this study were very promising - the investigators were able to show a
      significant increase in implantation rate (30% vs. 17%; p&lt;0.03), clinical pregnancy (48% vs.
      26%; p&lt;0.01) and ongoing pregnancy (39% vs. 20%; p&lt;0.01) for the patients receiving the
      aforementioned modified luteal support protocol.

      After the completion of this retrospective study the investigators are heading to prove the
      superiority of the modified luteal support protocol for ovulatory patients by conducting a
      prospective study.

      Materials &amp; Methods Study design - A prospective, randomized, blinded study. Primary endpoint
      - Ongoing pregnancy. Secondary endpoints - Implantation rate, clinical pregnancy. Study
      sample - According to the previous, retrospective study the investigators will need 31
      patients in each study arm in order to show an increase from 20% clinical pregnancy to 39%
      (confidence level 5%, beta error level 50%).

      The patients - The investigators will offer each patient treated in the unit for
      frozen-thawed embryo transfer to participate in the study. The randomization of the
      participants will be on the day of embryo transfer with a computer program on a 1:1
      enrollment ratio.

      All transfers will be performed by an experienced physician who will be blinded to the luteal
      support protocol.

      Both groups will be treated with the accepted progesterone luteal support - starting on
      ovulation day - vaginal progesterone 90 mg (Crinone; Merck Serono, Hellerup, Denmark) once a
      day.

      Study group - Patients in the study group will receive additional two injections - the first
      - recombinant hCG 250 mcg (Ovitrelle; Merck Serono) on the transfer day and the second -
      GnRH-agonist 0.1 mg (Decapeptyl; Ferring Pharmaceuticals Israel) 4 days after the embryo
      transfer day. Patients in the control group will receive no injection.

      B-hCG levels will be examined 12 days after embryo transfer and if positive ultrasound
      examinations will be performed as usual to document pregnancy outcome.

      The data - The investigators will use demographic data such as age, BMI, gynecological data
      as gravida, para, etiology of infertility and data about previous &amp; current IVF treatments
      such as number of treatments, stimulation protocol, hormone levels, number of oocytes,
      embryos' characteristics, etc.

      Statistics - Statistical analysis will be performed with Student's t-test and Chi square, as
      appropriate. Results will be presented as means Â± standard deviations; p&lt;0.05 will be
      considered significant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy</measure>
    <time_frame>About 10-12 weeks after embryo transfer</time_frame>
    <description>Number of viable pregnancies at about 10-12 weeks of gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>2 weeks after embryo transfer</time_frame>
    <description>Positive BhCG blood test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy</measure>
    <time_frame>About 3-4 weeks after embryo transfer</time_frame>
    <description>Visible intrauterine gestational sacs on ultrasound exam</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Embryo Transfer</condition>
  <condition>Luteal Support</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hCG (Choriogonadotropin alfa; Ovitrelle 250 mcg) on day of embryo transfer &amp; GnRH-agonist (Triptorelin acetate; Decapeptyl 0.1 mg) after 4 days In addition to the usual progesterone luteal support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The usual progesterone only luteal phase support.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Choriogonadotropin alfa</intervention_name>
    <arm_group_label>Study group</arm_group_label>
    <other_name>recombinant hCG</other_name>
    <other_name>Ovitrelle</other_name>
    <other_name>Ovidrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin acetate</intervention_name>
    <arm_group_label>Study group</arm_group_label>
    <other_name>GnRH-Agonist</other_name>
    <other_name>Decapeptyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-40 years old women

          -  Spontaneously ovulating women

          -  Treated in our IVF unit for frozen-thawed embryo transfer

          -  At least one top quality embryo

        Exclusion Criteria:

          -  PGD patients

          -  More than 4 previous embryo transfers
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eran Zilberberg, MD</last_name>
    <phone>+97235302882</phone>
    <email>eran.zilberberg@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raoul Orvieto, MD</last_name>
    <phone>+97235302882</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba medical center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eran Zilberberg, MD</last_name>
      <phone>+97235302882</phone>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Thurin A, Hausken J, HillensjÃ¶ T, Jablonowska B, Pinborg A, Strandell A, Bergh C. Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization. N Engl J Med. 2004 Dec 2;351(23):2392-402.</citation>
    <PMID>15575055</PMID>
  </reference>
  <reference>
    <citation>Le Lannou D, Griveau JF, Laurent MC, Gueho A, Veron E, Morcel K. Contribution of embryo cryopreservation to elective single embryo transfer in IVF-ICSI. Reprod Biomed Online. 2006 Sep;13(3):368-75.</citation>
    <PMID>16984767</PMID>
  </reference>
  <reference>
    <citation>Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C. Clinical rationale for cryopreservation of entire embryo cohorts in lieu of fresh transfer. Fertil Steril. 2014 Jul;102(1):3-9. doi: 10.1016/j.fertnstert.2014.04.018. Epub 2014 May 17. Review.</citation>
    <PMID>24842675</PMID>
  </reference>
  <reference>
    <citation>Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C, Thomas S. Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen-thawed embryo transfer in normal responders. Fertil Steril. 2011 Aug;96(2):344-8. doi: 10.1016/j.fertnstert.2011.05.050. Epub 2011 Jul 6.</citation>
    <PMID>21737072</PMID>
  </reference>
  <reference>
    <citation>Orvieto R, Fisch B, Feldberg D. Endometrial Preparation for Patients undergoing Frozen- Thawed Embryo Transfer Cycles. In: The Art &amp; Science of Assisted Reproductive Techniques. G. Allahbadia, R. asuray, R. Merchant, Eds. Jaypee Brothers Medical Publishers (P) Ltd. New Delhi, India, 2003, pp. 396-9.</citation>
  </reference>
  <reference>
    <citation>Navot D, Laufer N, Kopolovic J, Rabinowitz R, Birkenfeld A, Lewin A, Granat M, Margalioth EJ, Schenker JG. Artificially induced endometrial cycles and establishment of pregnancies in the absence of ovaries. N Engl J Med. 1986 Mar 27;314(13):806-11.</citation>
    <PMID>3951513</PMID>
  </reference>
  <reference>
    <citation>Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod. 2002 Sep;17(9):2287-99. Review.</citation>
    <PMID>12202415</PMID>
  </reference>
  <reference>
    <citation>Meldrum DR. Female reproductive aging--ovarian and uterine factors. Fertil Steril. 1993 Jan;59(1):1-5. Review.</citation>
    <PMID>8419194</PMID>
  </reference>
  <reference>
    <citation>Fatemi HM, Kyrou D, Bourgain C, Van den Abbeel E, Griesinger G, Devroey P. Cryopreserved-thawed human embryo transfer: spontaneous natural cycle is superior to human chorionic gonadotropin-induced natural cycle. Fertil Steril. 2010 Nov;94(6):2054-8. doi: 10.1016/j.fertnstert.2009.11.036. Epub 2010 Jan 25.</citation>
    <PMID>20097333</PMID>
  </reference>
  <reference>
    <citation>Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod. 2004 May;19(5):1176-80. Epub 2004 Apr 7.</citation>
    <PMID>15070873</PMID>
  </reference>
  <reference>
    <citation>Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod. 2006 Oct;21(10):2572-9. Epub 2006 Aug 22.</citation>
    <PMID>16926261</PMID>
  </reference>
  <reference>
    <citation>Orvieto R, Brengauz M, Feldman B. A novel approach to normal responder patient with repeated implantation failures--a case report. Gynecol Endocrinol. 2015 Jun;31(6):435-7. doi: 10.3109/09513590.2015.1005595. Epub 2015 Mar 3.</citation>
    <PMID>25731193</PMID>
  </reference>
  <reference>
    <citation>Haas J, Lantsberg D, Feldman N, Manela D, Machtinger R, Dar S, Rabinovici J, Orvieto R. Modifying the luteal phase support in natural cycle frozen-thawed embryo transfer improves cycle outcome. Gynecol Endocrinol. 2015;31(11):891-3. doi: 10.3109/09513590.2015.1075502. Epub 2015 Aug 18.</citation>
    <PMID>26288149</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2016</study_first_submitted>
  <study_first_submitted_qc>July 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>December 11, 2016</last_update_submitted>
  <last_update_submitted_qc>December 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Eran Zilberberg</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Frozen-thawed embryo transfer (FET)</keyword>
  <keyword>Luteal support</keyword>
  <keyword>Progesterone</keyword>
  <keyword>Natural cycle</keyword>
  <keyword>Cryopreservation</keyword>
  <keyword>IVF</keyword>
  <keyword>hCG</keyword>
  <keyword>GnRH-Agonist</keyword>
  <keyword>Pregnancy rate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

